Drug recall · November 12, 2025
Amoxicillin and Clavulanate Potassium for Oral Suspension USP recall
Why: Subpotent drug; Clavulanate Potassium component
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
- Lots / codes
Lot # 100062316, Exp Date: 01/2026
- Quantity
- 4680 cartons
- Company
- Teva Pharmaceuticals USA, Inc, Parsippany, NJ
- Distribution
- Distributed in three (3) States: MS, OH, CA.
- Initiated
- October 13, 2025 · Voluntary: Firm initiated
- Classified
- November 3, 2025
- Reported
- November 12, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amoxicillin / clavulanate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.